Navigating the limits of ribociclib in early breast cancer: questions from the NATALEE trial

We read with great interest the recent findings from the NATALEE trial on the efficacy of ribociclib in combination with nonsteroidal aromatase inhibitors (NSAI) as adjuvant therapy for HR-positive/HER2-negative early breast cancer, published in Annals of Oncology.1 While the study presents promising outcomes for certain patient populations, we would like to raise a few points for further consideration regarding the…